Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VERA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVera aligns with FDA on accelerated ORIGIN 3 timeline; full approval data expected Q3 2026
Filed June 2, 2026 · Period ending June 2, 2026 · ~1 min read
Key Changes
-
high
FDA agreed to earlier kidney function analysis from ORIGIN 3 trial supporting full approval of atacicept for IgA Nephropathy. Results now expected Q3 2026, ahead of prior schedule.
8-K disclosure view on EDGAR → -
high
Company plans to submit supplemental biologics license application for full approval in Q4 2026, pending positive Q3 results. Full approval would expand market access and remove post-approval study requirements.
8-K disclosure view on EDGAR →
Summary
Vera Therapeutics announced it has reached agreement with the FDA on an accelerated timeline for analyzing kidney function data from its pivotal ORIGIN 3 trial of atacicept in IgA Nephropathy. The revised plan moves the critical eGFR analysis forward to the third quarter of 2026, earlier than previously expected. This data will support the company's application for full FDA approval of its lead drug candidate.
For investors, this represents a meaningful de-risking and acceleration of Vera's regulatory pathway. Full approval typically expands insurance coverage, removes the uncertainty of confirmatory trial requirements, and strengthens the commercial profile versus accelerated approval. The company plans to file its supplemental application in Q4 2026 if results are positive.
Watch for the Q3 2026 data readout closely—it will determine whether Vera can proceed with the full approval filing and represents a binary catalyst for the stock. Any delay or negative results would likely force the company back to a longer development timeline.
Section-by-Section Diff
Event · Item 8.01 — Other Events
Item 8.01 — Other Events filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
the Company has aligned with the U.S. Food and Drug Administration on a revised, earlier ORIGIN 3 eGFR analysis plan to support the potential full approval of atacicept in adults with IgA Nephropathy. The eGFR results are now expected in the third quarter of 2026.
Vera announced FDA agreement on an accelerated timeline for the ORIGIN 3 trial's eGFR (kidney function) analysis supporting full approval of atacicept for IgA Nephropathy. The revised plan moves results forward to Q3 2026, earlier than previously expected. This is a key regulatory milestone for the company's lead drug candidate.
Added in current filing · verify on EDGAR →
Pending these results, the Company plans to submit a supplemental Biologics License Application for full approval of atacicept in the fourth quarter of 2026.
Contingent on positive Q3 2026 eGFR results, Vera plans to file a supplemental Biologics License Application (sBLA) in Q4 2026 seeking full FDA approval of atacicept. This filing would convert any existing accelerated approval to full approval, a critical commercial milestone that typically expands market access and removes post-approval study requirements.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify